A Phase 4 Study to Evaluate Safety and Effectiveness of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) With Ring Sideroblasts Who Require Red Blood Cell Transfusions in Participants Who Have Had Unsatisfactory Response to or Are Ineligible to Erythropoietin Based Therapy and in Participants With Transfusion Dependent Anemia Due to Beta-Thalassemia
Latest Information Update: 22 Nov 2024
Price :
$35 *
At a glance
- Drugs Luspatercept (Primary)
- Indications Beta-thalassaemia
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 27 Aug 2024 Planned primary completion date changed from 13 Apr 2026 to 17 Feb 2026.
- 01 May 2024 Planned End Date changed from 17 Feb 2026 to 13 Apr 2026.
- 01 May 2024 Planned primary completion date changed from 17 Feb 2026 to 13 Apr 2026.